Myeloid’s proprietary cell therapy technology has been developed by leading scientists in oncology, immunology, cell therapy, synthetic biology, and virology. We have developed a versatile and powerful platform to reprogram cells of the innate immune system. By targeting myeloid cells, our approach allows for diverse applications and the recruitment of the broader immune system. Our areas of interest include viruses, cancers, and autoimmune diseases.
With unrivaled expertise in immunology, and operating sites in North America (East and West Coast) and Europe, Nexelis is a leading provider of assay development and advanced laboratory testing services in the infectious diseases, metabolic diseases, and oncology fields. Our versatile team of scientists, working with our advanced technology platforms, were instrumental in the development, qualification, validation, and large-scale sample testing of assays that supported the FDA filing of almost 100 new molecular entities, including blockbuster vaccines, anti-viral drugs, and immunotherapy, gene and cell therapy products.